Syndax Pharmaceuticals Inc
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $172.4M
- Net income
- -$285.4M
- Total assets
- $529.7M
- Market cap
- $1.5B
- Operating margin
- -158.4%
- Net margin
- -165.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $172.4M
- Operating expenses
- $445.4M
- Operating income
- -$273.1M
- Income tax
- $433.0K
- Net income
- -$285.4M
- EPS (basic)
- $-3.29
- EPS (diluted)
- $-3.29
Balance sheet
- Total assets
- $529.7M
- Current assets
- $528.1M
- Total liabilities
- $465.1M
- Current liabilities
- $120.1M
- Shareholders’ equity
- $64.6M
Cash flow
- Operating cash flow
- -$323.0M
- Investing cash flow
- $290.0M
- Financing cash flow
- $13.7M
- Net cash flow
- -$19.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-3.29
- Shares outstanding
- 90.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 3, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $285.4M in FY2025.
- Revenue grew 11261% from FY2020 to FY2025.
- Trading 33% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Syndax Pharmaceuticals Inc.
Write a review
News about Syndax Pharmaceuticals Inc
News & sentiment via Polygon.io
